Diabetes, Vol 40, Issue 5 558-567, Copyright © 1991 by American Diabetes Association

ARTICLES

Normalization of Na(+)-K(+)-ATPase activity in isolated membrane fraction from sciatic nerves of streptozocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro

J Kim, H Kyriazi and DA Greene
Department of Biochemistry, University of Pittsburgh School of Medicine, Pennsylvania.

A myo-inositol-related defect in nerve Na(+)-K(+)-ATPase in experimental diabetes has been invoked in the pathogenesis of diabetic neuropathy, but the mechanism linking altered myo-inositol metabolism and Na(+)-K(+)-ATPase regulation in diabetic nerve is uncertain. Decreased Na(+)-K(+)-ATPase in diabetic rat nerve is normalized by aldose reductase inhibitors or dietary myo-inositol, which preserve normal nerve myo-inositol content in vivo. Decreased Na(+)-K(+)-ATPase in diabetic rabbit nerve is acutely reversed by exposure to protein kinase C agonists in vitro. This study explored the relationship between the myo-inositol-sensitive and protein kinase C-agonist-sensitive Na(+)-K(+)-ATPase defects in diabetic rat nerve. Ouabain-sensitive ATPase activity was measured in an enriched membrane fraction isolated from nondiabetic, streptozocin-induced diabetic, and myo-inositol-supplemented streptozocin-induced diabetic rats before and after the membranes were exposed to protein kinase C agonists in vitro. The decreased ouabain-sensitive ATPase activity in plasma membranes from untreated diabetic rats was increased after exposure to two structurally unrelated protein kinase C agonists; the normal ouabain-sensitive ATPase in plasma membranes from myo-inositol-supplemented diabetic rats was unaffected by protein kinase C agonists. The nonadditivity and implied equivalence of the Na(+)-K(+)-ATPase defect corrected by myo-inositol in vivo and by protein kinase C agonists in vitro are consistent with the postulated existence of a deficient myo-inositol-dependent phospholipid-derived protein kinase C agonist (presumably diacylglycerol) in diabetic nerve that regulates nerve Na(+)-K(+)-ATPase either directly or via a protein kinase C mechanism.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. A. Yorek, L. J. Coppey, J. S. Gellett, E. P. Davidson, X. Bing, D. D. Lund, and J. S. Dillon Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1067 - E1075. [Abstract] [Full Text] [PDF]

				M. G. Grossman, S. A. Ducey, S. S. Nadler, and A. S. Levy Meralgia Paresthetica: Diagnosis and Treatment J. Am. Acad. Ortho. Surg., September 1, 2001; 9(5): 336 - 344. [Abstract] [Full Text] [PDF]

				R. J Head, P. L McLennan, D. Raederstorff, R. Muggli, S. L Burnard, and E. J McMurchie Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids1 Am. J. Clinical Nutrition, January 1, 2000; 71(1): 386S - 392S. [Abstract] [Full Text] [PDF]

				J. Nakamura, N. Koh, F. Sakakibara, Y. Hamada, T. Hara, H. Sasaki, S. Chaya, T. Komori, E. Nakashima, K. Naruse, et al. Polyol Pathway Hyperactivity Is Closely Related to Carnitine Deficiency in the Pathogenesis of Diabetic Neuropathy of Streptozotocin-Diabetic Rats J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 897 - 902. [Abstract] [Full Text]